OmicsWay Corp.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer (NCT03521245) | OmicsWay Corp. | 2017-10-01 |
Track OmicsWay Corp. automatically
Every clearance here is in the API, with alerts when new ones post.